Ambrx
在场
Ambrx 的所有者是 Johnson & Johnson.
是其中之一......
- Forbes Global 2000 (#45);
- Fortune 500 (#42);
- Global Fortune 500 (#115);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Johnson & Johnson 是一家在股票代码 JNJ (US) 下上市的公司。
Johnson & Johnson 在 23 个国家有直接业务。Johnson & Johnson 拥有 65家子公司，其中包括 Abiomed、Ambrx 和 DePuy Synthes。
他们在：
涉及Johnson & Johnson的并购和融资。
- Johnson & Johnson 已收购 Ambrx (公布2024一月11号).
- Ambrx 刚刚宣布为 78 筹款数百万美元。 (公布2023三月13号).
高管
查看带有其 7 名主要高管的组织结构图
Ambrx 搜索最多的简介
- Daniel O'Connor, Chief Executive Officer, President and Director
- Sandra Aung, Chief Clinical Officer
- Ying Buechler, Chief Technology Officer
高管在Ambrx变化
- Andrew Aromando, Chief Operating Officer, 已经离开公司 (新闻发布的2024三月24号).
高管在Johnson & Johnson变化
- Scott Davis, Director, 正在办理退休 (新闻发布的2024九月11号).
- Kristen Mulholland 曾任 Head of Human Resources, Global Total Rewards, 将于 202410月1 升职为 Chief Human Resources Officer (新闻发布的2024八月26号).
- Peter Fasolo, Executive Vice President and Chief Human Resources Officer, 将于 202410月1 退休 (新闻发布的2024八月26号).
创建提醒
跟踪 Ambrx 的高管变动
药店
Johnson & Johnson 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Roche (瑞士)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Ambrx 的最新新闻稿
- Ambrx Announces Pricing of Initial Public Offering
- Ambrx Shareholders Approve Acquisition by Johnson & Johnson
- Ambrx - Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
- Ambrx - Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
- Ambrx - Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments
- Ambrx - ESMO 2023 Posters and ARX517 Slide Deck Available Here
- Ambrx - ESMO 2023 Abstracts Available Here
- Ambrx - Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress
- Ambrx - Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023
- Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference
- View more press releases Close
通过电子邮件
